Relationship of salusin-alpha and salusin-beta levels with atherosclerosis in patients undergoing haemodialysis

ABSTRACT

INTRODUCTION@#In patients undergoing haemodialysis, cardiovascular mortality and morbidity, characterised by accelerated atherosclerosis and increased inflammation, are elevated. Salusins are newly defined molecules in the atherosclerotic processes, and while salusin-alpha (Sal-α) acts as an antiatherogenic factor, salusin-beta (Sal-β) has a proatherogenic role. Their roles are as yet undefined in patients undergoing haemodialysis.@*METHODS@#In this cross-sectional study, salusin levels, carotid intima-media thickness (CIMT) from the common carotid artery and pulse wave velocity (PWV) were measured for 180 patients undergoing haemodialysis and 90 healthy controls.@*RESULTS@#Mean Sal-α and Sal-β levels in patients undergoing haemodialysis (Sal-α 726.4 ± 578.7 pg/mL; Sal-β 1,080.4 ± 757.1 pg/mL) and healthy controls (Sal-α 325.8 ± 303.7 pg/mL; Sal-β 268.1 ± 409.0 pg/mL) were determined. Negative correlation was observed between Sal-α levels and CIMT (patients undergoing haemodialysis r = -0.330, p < 0.0001; healthy controls r = -0.223, p = 0.035) and PWV (patients undergoing haemodialysis r = -0.210, p = 0.005; healthy controls r = -0.378, p < 0.0001) in both groups. In patients undergoing haemodialysis, positive correlation was observed between Sal-β/Sal-α ratio and CIMT (r = 0.190, p = 0.012) and PWV (r = 0.155, p = 0.041). On subgroup analysis, Sal-α levels were found to be low in patients with diabetes mellitus.@*CONCLUSION@#Patients undergoing haemodialysis have higher Sal-β and Sal-α levels, and their higher Sal-β/Sal-α ratio, in comparison with healthy controls, might have cardiovascular risk implications.